Skip to main content
Top
Published in: Journal of General Internal Medicine 12/2008

01-12-2008 | Original Article

Living with Hepatitis C: Qualitative Interviews with Hepatitis C-infected Veterans

Authors: Erik J. Groessl, Kimberly R. Weingart, Robert M. Kaplan, Jack A. Clark, Allen L. Gifford, Samuel B. Ho

Published in: Journal of General Internal Medicine | Issue 12/2008

Login to get access

Abstract

Background

Chronic hepatitis C (HCV) infection affects millions of people in the USA and prevalence rates are higher in US veterans. The consequences of HCV infection include reduced quality of life, liver damage, and reduced longevity.

Objective

Our objective was to describe the experiences of US veterans living with chronic HCV infection and use this information in the development of an HCV self-management intervention.

Methods

Twenty-two male HCV-infected veterans completed qualitative interviews. Participants were recruited via flyers and hepatitis C clinic providers at a major VA medical center. Participants were asked about their medical history, being diagnosed with HCV, and general experiences living with HCV.

Results

The study gathered the following findings: the impact of HCV on interpersonal relationships was pronounced, recovery from substance use disorders and getting care for HCV were connected, receiving the HCV diagnosis was more troubling to non-IV drug users, participants had misconceptions about HCV and its treatment, psychological problems were prevalent as were barriers to participating in antiviral treatment and HCV care in general.

Conclusion

The themes derived from our analysis indicate that affected veterans may benefit from interventions or support to improve HCV-related health education, social/relationship issues, psychological issues, and exploration of the connection between substance use recovery and motivation to get care for HCV infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325(2):98–104. Jul 11PubMed Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325(2):98–104. Jul 11PubMed
2.
go back to reference Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639–644. MarPubMed Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639–644. MarPubMed
3.
go back to reference Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556–562. Aug 19PubMedCrossRef Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556–562. Aug 19PubMedCrossRef
4.
go back to reference Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41(1):88–96. JanPubMedCrossRef Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41(1):88–96. JanPubMedCrossRef
5.
go back to reference Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology. 1997;26(3):521–526. SepPubMedCrossRef Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology. 1997;26(3):521–526. SepPubMedCrossRef
6.
go back to reference Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562–1569. OctPubMedCrossRef Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562–1569. OctPubMedCrossRef
7.
go back to reference Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 1997;42(12):2482–2486. DecPubMedCrossRef Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 1997;42(12):2482–2486. DecPubMedCrossRef
8.
go back to reference Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27(1):209–212. JanPubMedCrossRef Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27(1):209–212. JanPubMedCrossRef
9.
go back to reference Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299–1301. NovPubMedCrossRef Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299–1301. NovPubMedCrossRef
10.
go back to reference Glacken M, Kernohan G, Coates V. Diagnosed with Hepatitis C: a descriptive exploratory study. Int J Nurs Stud. 2001;38(1):107–116. FebPubMedCrossRef Glacken M, Kernohan G, Coates V. Diagnosed with Hepatitis C: a descriptive exploratory study. Int J Nurs Stud. 2001;38(1):107–116. FebPubMedCrossRef
11.
go back to reference Gifford SM, O’Brien ML, Bammer G, Banwell C, Stoove M. Australian women’s experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol. 2003;18(7):841–850. JulPubMedCrossRef Gifford SM, O’Brien ML, Bammer G, Banwell C, Stoove M. Australian women’s experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol. 2003;18(7):841–850. JulPubMedCrossRef
12.
go back to reference Groessl EJ, Weingart KR, Kaplan RM, Ho SB. Health-Related Quality of Life in HCV Infected Patients. Current Hepatitis Reports. 2007;6(4):169–175. Groessl EJ, Weingart KR, Kaplan RM, Ho SB. Health-Related Quality of Life in HCV Infected Patients. Current Hepatitis Reports. 2007;6(4):169–175.
13.
go back to reference Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. Sep 22PubMedCrossRef Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. Sep 22PubMedCrossRef
14.
go back to reference Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. Sep 26PubMedCrossRef Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. Sep 26PubMedCrossRef
15.
go back to reference Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355. Mar 2PubMed Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355. Mar 2PubMed
16.
go back to reference Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56(3):385–389. MarPubMedCrossRef Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56(3):385–389. MarPubMedCrossRef
17.
go back to reference National Institutes of Health. Management of Hepatitis C:2002 June 10–12, 2002 2002. National Institutes of Health. Management of Hepatitis C:2002 June 10–12, 2002 2002.
18.
go back to reference VA National Hepatitis C Program. VA Treatment Recommendations - Patients with Chronic Hepatitis C (Version 5.0). Federal Practitioner. September 2003;20(Suppl. 5). VA National Hepatitis C Program. VA Treatment Recommendations - Patients with Chronic Hepatitis C (Version 5.0). Federal Practitioner. September 2003;20(Suppl. 5).
19.
go back to reference Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: Effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262.PubMedCrossRef Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: Effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262.PubMedCrossRef
20.
go back to reference Cronan TA, Groessl E, Kaplan RM. The effects of social support and education interventions on health care costs. Arthritis Care Res. 1997;10(2):99–110. AprPubMedCrossRef Cronan TA, Groessl E, Kaplan RM. The effects of social support and education interventions on health care costs. Arthritis Care Res. 1997;10(2):99–110. AprPubMedCrossRef
21.
go back to reference Lorig KR, Ritter P, Stewart AL, et al. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care. 2001;39(11):1217–1223. NovPubMedCrossRef Lorig KR, Ritter P, Stewart AL, et al. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care. 2001;39(11):1217–1223. NovPubMedCrossRef
22.
go back to reference Lorig KR, Ritter PL, Gonzalez VM. Hispanic chronic disease self-management: a randomized community-based outcome trial. Nurs Res. 2003;52(6):361–369. Nov-DecPubMedCrossRef Lorig KR, Ritter PL, Gonzalez VM. Hispanic chronic disease self-management: a randomized community-based outcome trial. Nurs Res. 2003;52(6):361–369. Nov-DecPubMedCrossRef
23.
go back to reference Groessl EJ, Cronan TA. A cost analysis of self-management programs for people with chronic illness. Am J Community Psychol. 2000;28(4):455–480. AugPubMedCrossRef Groessl EJ, Cronan TA. A cost analysis of self-management programs for people with chronic illness. Am J Community Psychol. 2000;28(4):455–480. AugPubMedCrossRef
24.
go back to reference Cronan TA, Hay M, Groessl E, Bigatti S, Gallagher R, Tomita M. The effects of social support and education on health care costs after three years. Arthritis Care Res. 1998;11(5):326–334. OctPubMedCrossRef Cronan TA, Hay M, Groessl E, Bigatti S, Gallagher R, Tomita M. The effects of social support and education on health care costs after three years. Arthritis Care Res. 1998;11(5):326–334. OctPubMedCrossRef
25.
go back to reference Sankar A, Golin C, Simoni JM, Luborsky M, Pearson C. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S54–68. Dec 1PubMed Sankar A, Golin C, Simoni JM, Luborsky M, Pearson C. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S54–68. Dec 1PubMed
26.
go back to reference Crockett B, Gifford SM. “Eyes Wide Shut”: narratives of women living with hepatitis C in Australia. Women Health. 2004;39(4):117–137.PubMedCrossRef Crockett B, Gifford SM. “Eyes Wide Shut”: narratives of women living with hepatitis C in Australia. Women Health. 2004;39(4):117–137.PubMedCrossRef
27.
go back to reference Glacken M, Coates V, Kernohan G, Hegarty J. The experience of fatigue for people living with hepatitis C. J Clin Nurs. 2003;12(2):244–252. MarPubMed Glacken M, Coates V, Kernohan G, Hegarty J. The experience of fatigue for people living with hepatitis C. J Clin Nurs. 2003;12(2):244–252. MarPubMed
28.
go back to reference Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006;12(29):4665–4672. Aug 7PubMed Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006;12(29):4665–4672. Aug 7PubMed
29.
go back to reference Zickmund S, Hi EY, Masuda M, Ippolito L, LaBrecque DR. “They treat me like a leper” Stigatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.PubMedCrossRef Zickmund S, Hi EY, Masuda M, Ippolito L, LaBrecque DR. “They treat me like a leper” Stigatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.PubMedCrossRef
30.
go back to reference Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39(4):999–1007. AprPubMedCrossRef Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39(4):999–1007. AprPubMedCrossRef
31.
go back to reference Centers for Disease Control and Prevention. Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report. 1998;47:1–39. Centers for Disease Control and Prevention. Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report. 1998;47:1–39.
32.
go back to reference Davis M, Rhodes T, Martin A. Preventing hepatitis C: ‘common sense’, ‘the bug’ and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med. 2004;59(9):1807–1818. NovPubMedCrossRef Davis M, Rhodes T, Martin A. Preventing hepatitis C: ‘common sense’, ‘the bug’ and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med. 2004;59(9):1807–1818. NovPubMedCrossRef
33.
go back to reference Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004;99(5):621–633. MayPubMedCrossRef Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004;99(5):621–633. MayPubMedCrossRef
34.
go back to reference Tompkins CN, Wright NM, Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract. 2005;55(513):263–268. AprPubMed Tompkins CN, Wright NM, Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract. 2005;55(513):263–268. AprPubMed
35.
go back to reference Cullen W, Kelly Y, Stanley J, Langton D, Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Ir Med J. 2005;98(3):73–74. MarPubMed Cullen W, Kelly Y, Stanley J, Langton D, Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Ir Med J. 2005;98(3):73–74. MarPubMed
36.
go back to reference Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res. 2005;15(5):635–646. MayPubMedCrossRef Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res. 2005;15(5):635–646. MayPubMedCrossRef
37.
go back to reference Sheppard K, Hubbert A. The patient experience of treatment for hepatitis C. Gastroenterol Nurs. 2006;29(4):309–315. Jul-AugPubMedCrossRef Sheppard K, Hubbert A. The patient experience of treatment for hepatitis C. Gastroenterol Nurs. 2006;29(4):309–315. Jul-AugPubMedCrossRef
38.
go back to reference Kaplan R, Anderson J. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven; 1996: 309–322. Kaplan R, Anderson J. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven; 1996: 309–322.
39.
go back to reference Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol. 1982;1:61–80.CrossRef Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol. 1982;1:61–80.CrossRef
40.
go back to reference Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res. 1976;11(4):478–507. WinterPubMed Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res. 1976;11(4):478–507. WinterPubMed
41.
go back to reference Dollarhide AW, Groessl EJ, Ho SB. Determining current barriers to antiviral treatment in a cohort of U.S. veterans referred for HCV evaluation. Paper presented at: J Hepatology 2007. Dollarhide AW, Groessl EJ, Ho SB. Determining current barriers to antiviral treatment in a cohort of U.S. veterans referred for HCV evaluation. Paper presented at: J Hepatology 2007.
42.
go back to reference Sloan KL, Straits-Troster KA, Dominitz JA, Kivlahan DR. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. J Clin Gastroenterol. 2004;38(3):279–284. MarPubMedCrossRef Sloan KL, Straits-Troster KA, Dominitz JA, Kivlahan DR. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. J Clin Gastroenterol. 2004;38(3):279–284. MarPubMedCrossRef
44.
go back to reference Roselle GA, Danko LH, Kralovic SM, Simbartl LA, Kizer KW. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med. 2002;167(9):756–759. SepPubMed Roselle GA, Danko LH, Kralovic SM, Simbartl LA, Kizer KW. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med. 2002;167(9):756–759. SepPubMed
45.
go back to reference Groessl EJ, Weingart KR, Kaplan RM, Ho SB. Health-Related Quality of Life in HCV Infected Patients. Current Hepatitis Reports. in press. Groessl EJ, Weingart KR, Kaplan RM, Ho SB. Health-Related Quality of Life in HCV Infected Patients. Current Hepatitis Reports. in press.
46.
go back to reference Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800. AprPubMedCrossRef Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800. AprPubMedCrossRef
47.
Metadata
Title
Living with Hepatitis C: Qualitative Interviews with Hepatitis C-infected Veterans
Authors
Erik J. Groessl
Kimberly R. Weingart
Robert M. Kaplan
Jack A. Clark
Allen L. Gifford
Samuel B. Ho
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 12/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0790-y

Other articles of this Issue 12/2008

Journal of General Internal Medicine 12/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.